Spruce Biosciences (Spruce Biosciences) Total Current Assets : $85.87 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Spruce Biosciences's total current assets for the quarter that ended in Mar. 2024 was $85.87 Mil.

Spruce Biosciences Total Current Assets Historical Data

The historical data trend for Spruce Biosciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spruce Biosciences Total Current Assets Chart

Spruce Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

4.65

160.40

91.90

83.61

102.18

Spruce Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															137.24	124.13	111.14	102.18	85.87

Spruce Biosciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Spruce Biosciences's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	96.339	+	0	+	0	+	5.844
	=	102.18

Spruce Biosciences's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	81.154	+	0	+	0	+	4.711
	=	85.87

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Spruce Biosciences (NAS:SPRB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Spruce Biosciences's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	81.154	-	20.915	+	0.75 * 0	+	0.5 * 0
=	60.24

Spruce Biosciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of Spruce Biosciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Spruce Biosciences (Spruce Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080

Website

https://www.sprucebiosciences.com

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Executives

Percival Barretto-ko	director	611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii	officer: Chief Medical Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg	director, officer: Chief Executive Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways	director	C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Jonas Hansson	director	18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Healthcap Viii, L.p.	10 percent owner	18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Moghrabi Dina Chaya	director	22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Samir M. Gharib	officer: Chief Financial Officer	2655 PINE STREET, #6, SAN FRANCISCO CA 94115
Richard King	director, officer: Chief Executive Officer	C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131